On November 3, 2025 Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), reported that an abstract from its TUSCANY study of tuspetinib with standard of care venetoclax and azacitidine in patients with newly diagnosed AML has been selected for poster presentation at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition. The meeting is scheduled to take place December 6-9, 2025, in Orlando, Florida.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ASH Poster Presentation Details:
Title: TUSCANY Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy
Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I
Session Date: December 6, 2025
Session Time: 5:30 PM – 7:30 PM
Presentation Time: 5:30 PM – 7:30 PM
Room: OCCC – West Halls B3-B4
Publication Number: 1645
The abstract accepted for presentation can be viewed online at the ASH (Free ASH Whitepaper) conference website here, and will appear in the November supplemental issue of Blood. Please note that the actual presentation will include more recent updates and additional data not found in the abstract.
(Press release, Aptose Biosciences, NOV 3, 2025, View Source [SID1234659240])